Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
Lantern Pharma Inc. (LTRN), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on November 13, 2025. The filing announces the upcoming release of financial results for the third quarter ended September 30, 2025.
Key Financial Metrics
The provided filing text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and presentation (Exhibit 99.2) referenced in the filing but are not detailed in the 8-K body text itself.
Material Changes
No material changes to financial performance or operations are described in the text of this filing. The document serves solely as a notification of the release of Q3 2025 results.
Guidance, Outlook, and Management Commentary
Management will discuss financial and operating results for the third quarter ended September 30, 2025, during a conference call and live webinar on November 13, 2025. A presentation supporting these discussions is included as Exhibit 99.2. The filing explicitly states that the information in the press release and presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Presentation) for updated clinical trial timelines, pipeline milestones, and forward-looking guidance.
- Verify the date and time of the conference call to access management's commentary on the results.
- Confirm the company's status as an emerging growth company and any associated accounting election disclosures.